Monday, June 23, 2025 4:32:42 PM
Oh, I completely disagree with that idea.
In 14 years of riding the ugly AVXL rollercoaster, as many here also know, this stock gets tossed around like a ragdoll by the wall street trading game. Sometimes it's easy to see the technical trading patterns, when wall street creates them. Then, always, there comes an 'unexpected' slam down. I've come to believe that the MM's have the ability to manipulate the price up and down 1 dollar and 2 dollars, almost any time they like, and price will go to whatever target they intend it to go to. It's always very tricky to play alongside. Always an educated guess at best. I use the TA tools I find useful.and sit back and watch what happens. Candle sticks are ok, along with Fib targets, plotted for both directions , a rainbow of moving averages, rsi, stoch, volume, whatever you use if you understand the tools through experience and alot of study. It's Never just one tool. These days, I focus alot on support and resistance targets, head and shoulder patterns, Fibonacci math targets, and whenever the Frool says "nonsense" , I know I'm on target. 😛. I like my TA guys here, and pay attention to what they are seeing.
In 14 years of riding the ugly AVXL rollercoaster, as many here also know, this stock gets tossed around like a ragdoll by the wall street trading game. Sometimes it's easy to see the technical trading patterns, when wall street creates them. Then, always, there comes an 'unexpected' slam down. I've come to believe that the MM's have the ability to manipulate the price up and down 1 dollar and 2 dollars, almost any time they like, and price will go to whatever target they intend it to go to. It's always very tricky to play alongside. Always an educated guess at best. I use the TA tools I find useful.and sit back and watch what happens. Candle sticks are ok, along with Fib targets, plotted for both directions , a rainbow of moving averages, rsi, stoch, volume, whatever you use if you understand the tools through experience and alot of study. It's Never just one tool. These days, I focus alot on support and resistance targets, head and shoulder patterns, Fibonacci math targets, and whenever the Frool says "nonsense" , I know I'm on target. 😛. I like my TA guys here, and pay attention to what they are seeing.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
